Chimeric Antigen Receptor T-cell therapies

GPTKB entity

Predicate	Object
gptkbp:instanceOf	gptkb:immunotherapy
gptkbp:abbreviation	gptkb:CAR-T_therapies
gptkbp:administeredBy	intravenous infusion
gptkbp:cellType	T lymphocyte
gptkbp:component	transmembrane domain antigen recognition domain costimulatory domain intracellular signaling domain
gptkbp:countryOfOrigin	gptkb:China gptkb:Europe gptkb:United_States
gptkbp:developedBy	gptkb:Carl_June gptkb:Michel_Sadelain
gptkbp:firstFDAApproval	2017
gptkbp:firstFDAApprovedProduct	gptkb:Kymriah gptkb:Yescarta
gptkbp:generation	first generation second generation third generation fourth generation
gptkbp:mechanismOfAction	genetically engineered T cells express chimeric antigen receptors
gptkbp:notableProduct	gptkb:Carvykti gptkb:Abecma gptkb:Tecartus gptkb:Kymriah gptkb:Yescarta gptkb:Breyanzi
gptkbp:processor	cell expansion leukapheresis lymphodepleting chemotherapy ex vivo genetic modification
gptkbp:regulates	gptkb:FDA gptkb:EMA
gptkbp:researchArea	autoimmune diseases solid tumors
gptkbp:riskFactor	infection B-cell aplasia hypogammaglobulinemia
gptkbp:sideEffect	neurotoxicity cytokine release syndrome
gptkbp:target	tumor-associated antigens
gptkbp:type	gptkb:gene_therapy personalized medicine
gptkbp:usedFor	gptkb:cancer multiple myeloma diffuse large B-cell lymphoma B-cell acute lymphoblastic leukemia
gptkbp:bfsParent	gptkb:CAR-T_cell_therapies
gptkbp:bfsLayer	6
https://www.w3.org/2000/01/rdf-schema#label	Chimeric Antigen Receptor T-cell therapies